Cancer cell plasticity and MHC-II-mediated immune tolerance promote breast cancer metastasis to lymph nodes.


Journal

The Journal of experimental medicine
ISSN: 1540-9538
Titre abrégé: J Exp Med
Pays: United States
ID NLM: 2985109R

Informations de publication

Date de publication:
04 09 2023
Historique:
received: 28 10 2022
revised: 10 04 2023
accepted: 25 05 2023
pmc-release: 21 12 2023
medline: 23 6 2023
pubmed: 21 6 2023
entrez: 21 6 2023
Statut: ppublish

Résumé

Tumor-draining lymph nodes (TDLNs) are important for tumor antigen-specific T cell generation and effective anticancer immune responses. However, TDLNs are often the primary site of metastasis, causing immune suppression and worse outcomes. Through cross-species single-cell RNA-Seq analysis, we identified features defining cancer cell heterogeneity, plasticity, and immune evasion during breast cancer progression and lymph node metastasis (LNM). A subset of cancer cells in the lymph nodes exhibited elevated MHC class II (MHC-II) gene expression in both mice and humans. MHC-II+ cancer cells lacked costimulatory molecule expression, leading to regulatory T cell (Treg) expansion and fewer CD4+ effector T cells in TDLNs. Genetic knockout of MHC-II reduced LNM and Treg expansion, while overexpression of the MHC-II transactivator, Ciita, worsened LNM and caused excessive Treg expansion. These findings demonstrate that cancer cell MHC-II expression promotes metastasis and immune evasion in TDLNs.

Identifiants

pubmed: 37341991
pii: 214183
doi: 10.1084/jem.20221847
pmc: PMC10286805
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : NHLBI NIH HHS
ID : T32 HL007627
Pays : United States
Organisme : NCI NIH HHS
ID : T32 CA251062
Pays : United States
Organisme : NCI NIH HHS
ID : K22 CA230315
Pays : United States
Organisme : NIAID NIH HHS
ID : R21 AI097745
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA045508
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL128168
Pays : United States
Organisme : NCI NIH HHS
ID : F32 CA275298
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA284372
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA284603
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA214913
Pays : United States
Organisme : NCI NIH HHS
ID : K00 CA234940
Pays : United States

Informations de copyright

© 2023 Lei et al.

Références

Sci Immunol. 2021 Sep 10;6(63):eabg3551
pubmed: 34516744
Nucleic Acids Res. 2015 Apr 20;43(7):e47
pubmed: 25605792
Lancet Oncol. 2014 Nov;15(12):1303-10
pubmed: 25439688
Nat Protoc. 2013 Nov;8(11):2281-2308
pubmed: 24157548
Ann Surg Oncol. 2020 Nov;27(12):4810-4818
pubmed: 32720039
Mucosal Immunol. 2021 Mar;14(2):443-454
pubmed: 33139845
Cell Rep. 2020 Mar 24;30(12):4110-4123.e4
pubmed: 32209472
Cell. 2008 May 16;133(4):704-15
pubmed: 18485877
BMC Bioinformatics. 2018 Nov 6;19(1):404
pubmed: 30400809
Nat Commun. 2021 May 11;12(1):2582
pubmed: 33976133
Cell Rep. 2021 Feb 9;34(6):108748
pubmed: 33567282
Curr Opin Immunol. 2008 Dec;20(6):669-75
pubmed: 18852045
JAMA Otolaryngol Head Neck Surg. 2019 Apr 01;145(4):352-360
pubmed: 30844021
Sci Immunol. 2021 Oct;6(64):eabg7836
pubmed: 34597124
Cell. 2014 Aug 28;158(5):1094-1109
pubmed: 25171410
JAMA. 2011 Feb 9;305(6):569-75
pubmed: 21304082
Nat Rev Immunol. 2022 Mar;22(3):158-172
pubmed: 34155388
Nature. 2020 Sep;585(7823):113-118
pubmed: 32814895
Trends Cell Biol. 2019 Mar;29(3):212-226
pubmed: 30594349
Cell Stem Cell. 2021 Nov 4;28(11):1922-1935.e5
pubmed: 34529935
Nat Commun. 2018 May 29;9(1):2113
pubmed: 29844317
Nature. 2022 May;605(7911):728-735
pubmed: 35545675
Cell. 2018 Nov 15;175(5):1307-1320.e22
pubmed: 30392957
Curr Protoc Immunol. 2001 May;Chapter 20:Unit 20.2
pubmed: 18432775
Vaccine. 2008 Dec 30;26 Suppl 8:I86-93
pubmed: 19388171
Nat Cell Biol. 2019 Jan;21(1):44-53
pubmed: 30602762
Comput Struct Biotechnol J. 2021 Jun 30;19:3796-3798
pubmed: 34285779
Am J Transplant. 2004 Oct;4(10):1614-27
pubmed: 15367216
Nat Methods. 2017 Mar;14(3):309-315
pubmed: 28114287
Cancer Discov. 2019 Aug;9(8):1102-1123
pubmed: 31197017
PLoS One. 2011;6(8):e24226
pubmed: 21918685
Immunity. 2021 Sep 14;54(9):2117-2132.e7
pubmed: 34525340
Nat Biomed Eng. 2021 Dec;5(12):1426-1436
pubmed: 34282290
Cancer Res. 2017 Aug 1;77(15):3982-3989
pubmed: 28428275
Nat Commun. 2021 Feb 17;12(1):1088
pubmed: 33597522
Curr Opin Immunol. 2018 Aug;53:64-73
pubmed: 29698919
Sci Rep. 2017 Dec 4;7(1):16878
pubmed: 29203879
Science. 2022 Sep 9;377(6611):1180-1191
pubmed: 35981096
Mol Oncol. 2017 Jul;11(7):781-791
pubmed: 28590032
J Natl Cancer Inst. 2015 Jun 10;107(9):
pubmed: 26063793
Nat Med. 2018 May;24(5):541-550
pubmed: 29686425
Front Immunol. 2018 Sep 25;9:2144
pubmed: 30319613
Cancer Discov. 2020 Feb;10(2):232-253
pubmed: 31699795
Nat Med. 2020 Aug;26(8):1271-1279
pubmed: 32572264
Nat Biotechnol. 2018 Jun;36(5):411-420
pubmed: 29608179
Cell Syst. 2015 Dec 23;1(6):417-425
pubmed: 26771021
Oncogenesis. 2021 Oct 5;10(10):66
pubmed: 34611125
Mol Microbiol. 2010 Jun;76(6):1358-75
pubmed: 20398214
Cancer Res. 2015 Jul 1;75(13):2749-59
pubmed: 25948589
Bioinformatics. 2020 Apr 15;36(8):2628-2629
pubmed: 31882993
Cell. 2016 Dec 1;167(6):1540-1554.e12
pubmed: 27912061
Science. 2018 Mar 23;359(6382):1403-1407
pubmed: 29567713
Science. 2019 Feb 8;363(6427):644-649
pubmed: 30733421
Front Oncol. 2018 Feb 21;8:36
pubmed: 29527513
Nature. 2018 Apr;556(7702):463-468
pubmed: 29670281
J Virol. 2007 Apr;81(7):3487-94
pubmed: 17202212
JCI Insight. 2018 Dec 20;3(24):
pubmed: 30568030
Sci Transl Med. 2018 Jul 18;10(450):
pubmed: 30021886
Cells. 2021 Mar 12;10(3):
pubmed: 33808959
Cancers (Basel). 2019 Jun 17;11(6):
pubmed: 31213009
BMC Bioinformatics. 2013 Jan 16;14:7
pubmed: 23323831
Nat Biotechnol. 2014 Apr;32(4):381-386
pubmed: 24658644
Nature. 2017 Jan 5;541(7635):41-45
pubmed: 27974793
Nucleic Acids Res. 2016 May 5;44(8):e71
pubmed: 26704973
Nat Commun. 2018 Sep 4;9(1):3588
pubmed: 30181541
Cell. 2019 Jun 13;177(7):1888-1902.e21
pubmed: 31178118
Cell. 2004 Jun 25;117(7):927-39
pubmed: 15210113
Cell. 2017 Dec 14;171(7):1611-1624.e24
pubmed: 29198524
Nature. 2022 Jun;606(7915):797-803
pubmed: 35705814
Front Immunol. 2011 Oct 04;2:48
pubmed: 22566838
Cell Rep. 2017 May 9;19(6):1189-1201
pubmed: 28494868
J Exp Med. 2005 Apr 4;201(7):1061-7
pubmed: 15809351
Nucleic Acids Res. 2020 Nov 4;48(19):e113
pubmed: 32997146
Science. 2018 Mar 23;359(6382):1408-1411
pubmed: 29567714
Cell. 2022 May 26;185(11):1924-1942.e23
pubmed: 35525247
Clin Cancer Res. 2019 Apr 15;25(8):2392-2402
pubmed: 30463850
Front Immunol. 2019 May 07;10:1033
pubmed: 31134089
Nature. 2022 Jun;606(7915):791-796
pubmed: 35322234
J Exp Med. 2013 Jul 29;210(8):1509-28
pubmed: 23878309
Blood. 2016 Aug 25;128(8):e20-31
pubmed: 27365425
J Clin Oncol. 2011 Jul 1;29(19):2628-34
pubmed: 21606433
Cancer Cell. 2020 Nov 9;38(5):685-700.e8
pubmed: 33007259
JCI Insight. 2018 Dec 6;3(23):
pubmed: 30518694
Anticancer Res. 2017 Apr;37(4):1773-1778
pubmed: 28373440
Nat Immunol. 2019 Apr;20(4):471-481
pubmed: 30778241
Cancer Cell. 2020 Sep 14;38(3):412-423.e9
pubmed: 32679107

Auteurs

Pin-Ji Lei (PJ)

Department of Radiation Oncology, Edwin L. Steele Laboratories, Massachusetts General Hospital Cancer Center, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.

Ethel R Pereira (ER)

Department of Radiation Oncology, Edwin L. Steele Laboratories, Massachusetts General Hospital Cancer Center, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.

Patrik Andersson (P)

Department of Radiation Oncology, Edwin L. Steele Laboratories, Massachusetts General Hospital Cancer Center, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.

Zohreh Amoozgar (Z)

Department of Radiation Oncology, Edwin L. Steele Laboratories, Massachusetts General Hospital Cancer Center, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.

Jan Willem Van Wijnbergen (JW)

Department of Radiation Oncology, Edwin L. Steele Laboratories, Massachusetts General Hospital Cancer Center, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.

Meghan J O'Melia (MJ)

Department of Radiation Oncology, Edwin L. Steele Laboratories, Massachusetts General Hospital Cancer Center, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.

Hengbo Zhou (H)

Department of Radiation Oncology, Edwin L. Steele Laboratories, Massachusetts General Hospital Cancer Center, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology , Cambridge, MA, USA.

Sampurna Chatterjee (S)

Department of Radiation Oncology, Edwin L. Steele Laboratories, Massachusetts General Hospital Cancer Center, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.

William W Ho (WW)

Department of Radiation Oncology, Edwin L. Steele Laboratories, Massachusetts General Hospital Cancer Center, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.

Jessica M Posada (JM)

Department of Radiation Oncology, Edwin L. Steele Laboratories, Massachusetts General Hospital Cancer Center, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.

Ashwin S Kumar (AS)

Department of Radiation Oncology, Edwin L. Steele Laboratories, Massachusetts General Hospital Cancer Center, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
Harvard-MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology , Cambridge, MA, USA.

Satoru Morita (S)

Department of Radiation Oncology, Edwin L. Steele Laboratories, Massachusetts General Hospital Cancer Center, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.

Lutz Menzel (L)

Department of Radiation Oncology, Edwin L. Steele Laboratories, Massachusetts General Hospital Cancer Center, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.

Charlie Chung (C)

Cold Spring Harbor Laboratory , Cold Spring Harbor, NY, USA.

Ilgin Ergin (I)

Cold Spring Harbor Laboratory , Cold Spring Harbor, NY, USA.

Dennis Jones (D)

Department of Pathology and Laboratory Medicine, School of Medicine, Boston University, Boston, MA, USA.

Peigen Huang (P)

Department of Radiation Oncology, Edwin L. Steele Laboratories, Massachusetts General Hospital Cancer Center, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.

Semir Beyaz (S)

Cold Spring Harbor Laboratory , Cold Spring Harbor, NY, USA.

Timothy P Padera (TP)

Department of Radiation Oncology, Edwin L. Steele Laboratories, Massachusetts General Hospital Cancer Center, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH